Heteromultivalent liposomal nanoconstructs for enhanced targeting and shear-stable binding to active platelets for site-selective vascular drug delivery

Biomaterials

Volumn 32, Issue 35, 2011, Pages 9504-9514

  Modery, Christa L ^a   Ravikumar, Madhumitha ^a   Wong, Timothy L ^a   Dzuricky, Michael J ^a   Durongkaveroj, Nat ^a   Sen Gupta, Anirban ^a  

^a Case Western Reserve University   (United States)

Author keywords

Drug delivery; Flow chamber; Liposomes; Platelets; Vascular disease

Indexed keywords

ACTIVATED PLATELETS; BINDING STRENGTH; DELIVERY VEHICLE; FLOW CHAMBERS; INTEGRINS; LOW-TO-HIGH; P-SELECTIN; PARALLEL PLATE FLOW CHAMBER; RGD PEPTIDE; SIDE EFFECT; SITE SELECTIVE; SURFACE-MODIFIED; SYNERGISTIC MECHANISM; THERAPEUTIC INDEX; VASCULAR DISEASE;

DRUG DELIVERY; EXCITONS; FLOW CYTOMETRY; LIPOSOMES; PARALLEL FLOW; PEPTIDES; PHOSPHOLIPIDS; PLATELETS;

SHEAR FLOW;

ALPHA2 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; BETA3 INTEGRIN; EWVDV PEPTIDE; LIPOSOME; PADGEM PROTEIN; PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; BINDING KINETICS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN TISSUE; MOLECULAR INTERACTION; PRIORITY JOURNAL; SHEAR STRESS; SURFACE PROPERTY; THROMBOCYTE;

AMINO ACID SEQUENCE; BLOOD PLATELETS; BLOOD VESSELS; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; HUMANS; LIGANDS; LIPOSOMES; MICROSCOPY, FLUORESCENCE; MOLECULAR SEQUENCE DATA; NANOSTRUCTURES; OLIGOPEPTIDES; PLATELET ACTIVATION; PROTEIN BINDING; RECEPTORS, CELL SURFACE;

EID: 80053581735     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.08.067     Document Type: Article

References (41)

1. Heart disease and stroke statistics 2010 July, American Heart Association, Available from URL:, Online. http://www.heart.org/HEARTORG/General/Heart-and-Stroke-Association-Statistics_UCM_319064_SubHomePage.jsp.
2. Sen Gupta A. Nanomedicine approaches in vascular disease: a review. Nanomedicine 2011, Epub ahead of print.
3. Torchilin V.P. Targeting of drugs and drug carriers within the cardiovascular system. Adv Drug Deliv Rev 1995, 17:75-101.
4. Labhasetwar V., Song C., Levy R.J. Nanoparticle drug delivery system for restenosis. Adv Drug Deliv Rev 1997, 24:63-85.
5. Phillips D.R., Conley P.B., Sinha U., Andre P. Therapeutic approaches in arterial thrombosis. J Thromb Haemost 2005, 3:1577-1589.
6. Lanza G.M., Marsh J.N., Hu G., Scott M.J., Schmieder A.H., Caruthers S., et al. Rational for a nanomedicine approach to thrombolytic therapy. Stroke 2010, 41:SS442-SS444.
7. Wickline S.A., Neubauer A.M., Winter P., Caruthers S., Lanza G. Applications of nanotechnology to atherosclerosis, thrombosis and vascular biology. Arterioscler Thromb Vasc Biol 2006, 26:435-441.
8. Brieger D., Topol E. Local drug delivery systems and prevention of restenosis. Cardiovasc Res 1997, 35:405-413.
9. Eccleston D.S., Lincoff A.M. Catheter-based drug delivery for restenosis. Adv Drug Deliv Rev 1997, 24:31-43.
10. Fattori R., Piva T. Drug-eluting stents in vascular intervention. Lancet 2003, 361:247-249.
11. Daemen J., Wenaweser P., Juni P., Boersma E., Serruys P.W., Windecker S. Late coronary stent thrombosis following drug-eluting stent implantation in routine clinical practice; 4 year follow up of 8146 patients from Bern and Rotterdam. Eur Heart J 2007, 28(Abs Sup):509.
12. Joner M., Finn A.V., Farb A., Mont E.K., Kolodgie F.D., Ladych E., et al. Pathology of drug eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202.
13. Virmani R., Kolodgie F.D., Farb A. Drug-eluting stents: are they really safe?. Am Heart Hosp J 2004, 2:85-88.
14. Bennet J.S., Berger B.W., Billings P.C. The structure and function of platelet integrins. J Thromb Haemost 2009, 7(Suppl. 1):200-205.
15. Plow E.F., Pierschbacher M.D., Ruoslahti E., Marguerie G.A., Ginsberg M.H. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci USA 1985, 82:8057-8061.
16. Sen Gupta A., Huang G., Lestini B.J., Sagnella S., Kottke-Marchant K., Marchant R.E. RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system. J Thromb Haemost 2005, 93:106-114.
17. Huang G., Zhou Z., Srinivasan R., Penn M.S., Kottke-Marchant K., Marchanst R.E., et al. Affinity manipulation of surface-conjugated RGD-peptide to modulate binding of liposomes to activated platelets. Biomaterials 2008, 29:1676-1685.
18. Merten M., Thiagarajan P. P-selectin in arterial thrombosis. Z Kardiol 2004, 93:855-863.
19. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
20. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 2005, 96:612-616.
21. Ruggeri Z.M. Platelets in atherothrombosis. Nat Med 2002, 8:1227-1234.
22. Davi G., Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007, 357:2482-2494.
23. Steinhubl S.R., Newby L.K., Sabatine M., Uchiyama S., Endres M., Avezum A., et al. Platelets and atherothrombosis: an essential role for inflammation in vascular disease - a review. Int J Angiol 2005, 14:211-217.
24. Gawaz M., Stellos K., Langer H.F. Platelets modulate atherogenesis and progression of atherosclerotic plaques via interaction with progenitor and dendritic cells. J Thromb Haemost 2007, 6:235-242.
25. Massberg S., Brand K., Gruner S., Page S., Muller E., Muller I., et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002, 196:887-896.
26. Klinger M.H.F. Platelets and inflammation. Anat Embryol 1997, 196:1-11.
27. Srinivasan R., Marchant R.E., Sen Gupta A. In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes. J Biomed Mater Res A 2010, 93(3):1004-1015.
28. Davie E.W., Fujikawa K., Kisiel W. The coagulation cascade: initiation, maintenance and regulation. Biochemistry 1991, 30:10363-10370.
29. Furie B., Furie B.C. Molecular and cellular biology of blood coagulation. N Engl J Med 1992, 326:800-806.
30. Molenaar T.J.M., Twisk J., de Haas S.A.M., Peterse N., Vogelnaar B.J.C.P., van Leeuwen S.H., et al. P-selectin as a candidate target in atherosclerosis. Biochem Pharmacol 2003, 66:859-866.
31. Appeldoorn C.C.M., Molenaar T.J.M., Bonnefoy A., van Leeuwen S.H., Vandervoort P.A.H., Hoylaerts M.F., et al. Rational optimization of a short human P-selectin binding peptide leads to nanomolar affinity antagonists. J Biol Chem 2003, 278:10201-10207.
32. West J. Modification of materials with bioactive peptides. Methods Mol Biol 2004, 238:113-122.
33. Nauman E.A., Risic K.J., Keaveny T.M., Satcher R.L. Quantitative assessment of steady and pulsatile flow fields in a parallel plate flow chamber. Ann Biomed Eng 1999, 27:194-199.
34. Bacabac R.G., Smit T.H., Cowin S.C., Van Loon J.J.W.A., Nieuwstadt F.T.M., Heethaar R., et al. Dynamic shear stress in parallel plate flow chamber. J Biomech 2005, 38:159-167.
35. Sakhalkar H.S., Dalal M.K., Salem A.K., Ansari R., Fu J., Klanl M.F., et al. Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc Natl Acad Sci USA 2003, 100:15895-15900.
36. Cuvelier S.L., Patel K.D. Studying leukocyte rolling and adhesion in vitro under flow conditions. Methods Mol Biol 2005, 290:331-342.
37. Otto M., Klein C.L., Kohler H., Wagner M., Rohrig O., Kirkpatrick J. Dynamic blood cell contact with biomaterials: validation of a flow chamber system according to international standard. J Mater Sci Mater Med 1997, 8(3):119-128.
38. Saul J.M., Annapragada A.V., Bellamkonda R.V. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release 2006, 114:277-287.
39. Laginha K., Mumbengegwi D., Allen T. Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. Biochim Biophys Acta 2005, 1711:25-32.
40. Charoenphol P., Huang R.B., Eniola-Adefeso O. Roles of particle size and hemodynamics on the efficacy of spherical vascular-targeted drug carriers. Biomaterials 2010, 31(6):1392-1402.
41. Huang R.B., Morcherla S., Heslinga M.J., Charoenphol P., Eniola-Adefeso O. Dynamic and cellular interactions of nanoparticles in vascular-targeted drug delivery. Mol Membr Biol 2010, 27(4-6):190-205.